Dr Bee Yong Mong
Head and Senior Consultant, Department of Endocrinology, Singapore General Hospital;Vice-President, Diabetes Singapore
Dr David Sim
Cardiologist, Heart Failure Program Director, National Heart Center Singapore; Immediate past president of Heart Failure Society (Singapore)
Dr Phua Ling Yaw
Family Physician Partner, Parkway Shenton Family Medical Clinic, Singapore
 

Uncovering the Risk: Heart Failure in Diabetic Patients: Value of the cardiac biomarker NT-proBNP

KEY TAKEAWAYS

  • Learn more about the role of NT-proBNP as a predictive biomarker for HF in individuals with T2DM, and gain insights on the following topics:
    • Prevalence and burden of T2DM and its association with HF
    • Assessing HF risk in individuals with T2DM
    • Using NT-proBNP as a biomarker for HF in T2DM
    • Guidelines on the use of NT-proBNP in T2DM

About the course

The prevalence of type 2 diabetes mellitus (T2DM) is increasing worldwide, accounting for around half a billion cases in 2021 alone. In addition, the risk factors for both T2DM and heart failure (HF) commonly overlap, with a magnified risk of HF in individuals with T2DM. This warrants further research into the risk assessment of HF.

 

Developed in collaboration with 3 regional experts across various specialties, the Heart Failure in Type 2 Diabetes Mellitus: Value of the cardiac biomarker NT-proBNP CME module focuses on the role of NT-proBNP as a predictive biomarker for HF in individuals with T2DM.

Contributors

Dr David Sim

Senior Consultant
Department of Cardiology
National Heart Centre Singapore

Past President
Heart Failure Society Singapore

Dr Bee Yong Mong

Head and Senior Consultant
Department of Endocrinology
Singapore General Hospital

Vice-President
Diabetes Singapore

Dr Phua Ling Yaw

Family Physician Partner
Parkway Shenton Family Medical Clinic Singapore

Earn CPD/CME Points
Learn on-demand at MIMS
Gain certification upon completion
Free registration

Learning outcomes

Upon completion of this module, participants will gain insights into the following topics:

  • Prevalence and burden of T2DM and its association with HF
  • Assessing HF risk in individuals with T2DM
  • Using NT-proBNP as a biomarker for HF in T2DM
  • Guidelines on the use of NT-proBNP in T2DM

Course details

Date: Available till July 2023
Location: Virtual, On-demand on the MIMS platform
(Link will be provided upon registration of interest)
Format: Powerpoint deck
Time: Around 1h for completion

1 CME / CPD point is provided upon successful completion of the module quiz. Sign up now to get access to the free course!

Updates from Leading Experts

STRONG-HF: Post-discharge Heart Failure Management and Implementation of GDMT Heart Failure Therapy

Prof Alexandre Mebazaa shares the key results and highlights from the STRONG-HF study that assessed the safety, tolerability of optimization of guideline directed medical therapy. [...]

Read...

CANVAS study: NT-proBNP and CVD risk reduction

Can you give us a short description of the CANVAS program? The CANVAS program was a set of two trials, whose goal was to evaluate the role of an SGLT2...

1 July 2021
Dr James L Januzzi